GeoVax: A Beacon of Transparency and Innovation in Vaccine Development

GeoVax Labs, Inc. (Nasdaq: GOVX), a leading biotechnology company specializing in immunotherapies and vaccines against infectious diseases and cancers, has pledged continued support for vaccine innovation, transparency, and public health. The company's commitment to these principles aligns with the anticipated priorities of the new HHS administration, focusing on vaccine safety, diversification, and domestic biosecurity.

GeoVax's vaccine development programs, including GEO-CM04S1 and GEO-MVA, are designed to address critical public health needs, particularly among immunocompromised populations. The company's proprietary Modified Vaccinia Ankara (MVA) platform offers a promising alternative to other vaccine technologies such as mRNA, providing broad-spectrum, durable immunity across multiple infectious diseases via a recognized safe vaccine platform.

Key initiatives supporting the goals for vaccine safety and transparency include:

1. Diversified Vaccine Development: GeoVax's GEO-CM04S1, a next-generation COVID-19 vaccine, and GEO-MVA, a dual-purpose Mpox and smallpox vaccine, align with the advocacy for alternative vaccine platforms beyond mRNA. These vaccines are designed to offer long-term immunity with a well-documented safety profile.
2. Transparency as a Pillar of Public Trust: As David Dodd, Chairman and CEO of GeoVax, has emphasized, restoring trust in vaccines requires clear communication, open regulatory processes, and full transparency regarding safety, efficacy, and potential risks. GeoVax supports the call for greater industry accountability and public engagement, ensuring that vaccine development aligns with the highest standards of ethical science.
3. Strengthening U.S. Biosecurity: GeoVax's anticipated domestic vaccine manufacturing capabilities reinforce the bipartisan legislative commitment to reducing dependence on foreign pharmaceutical supply chains, thereby enhancing national pandemic preparedness.

GeoVax's commitment to ethical vaccine development and public confidence is evident in its approach to open regulatory processes, rigorous safety standards, and public access to data. These principles align with the call for increased scrutiny and transparency in vaccine development and approval, as highlighted in a recent op-ed by Dodd (https://www.genengnews.com/topics/translational-medicine/a-call-to-action-building-vaccine-trust-through-transparency/).

In conclusion, GeoVax's dedication to vaccine innovation, transparency, and public health positions the company as a vital partner in safeguarding national and global public health. By prioritizing these principles, GeoVax is well-equipped to support the new HHS administration's goals of strengthening public trust, reducing regulatory opacity, and ensuring vaccine safety through independent oversight. As the company continues to advance its vaccine pipeline, it remains committed to delivering next-generation vaccines and advanced vaccine manufacturing technology that enhance biosecurity, public health resilience, and vaccine confidence.